Cargando…

Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?

The fascinating similarity between the SARS-CoV and SARS-CoV-2, inspires scientific community to investigate deeper into the SARS-CoV proteases such as main protease (Mpro) and papain-like protease (PLpro) and their inhibitors for the discovery of SARS-CoV-2 protease inhibitors. Because of the simil...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Sk Abdul, Banerjee, Suvankar, Gayen, Shovanlal, Jha, Tarun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880840/
https://www.ncbi.nlm.nih.gov/pubmed/33618158
http://dx.doi.org/10.1016/j.ejmech.2021.113294
_version_ 1783650761491611648
author Amin, Sk Abdul
Banerjee, Suvankar
Gayen, Shovanlal
Jha, Tarun
author_facet Amin, Sk Abdul
Banerjee, Suvankar
Gayen, Shovanlal
Jha, Tarun
author_sort Amin, Sk Abdul
collection PubMed
description The fascinating similarity between the SARS-CoV and SARS-CoV-2, inspires scientific community to investigate deeper into the SARS-CoV proteases such as main protease (Mpro) and papain-like protease (PLpro) and their inhibitors for the discovery of SARS-CoV-2 protease inhibitors. Because of the similarity in the proteases of these two corona viruses, there is a greater chance for the previous SARS-CoV Mpro and PLpro inhibitors to provide effective results against SARS-CoV-2. In this context, the molecular fragments from the SARS-CoV protease inhibitors through the fragment-based drug design and discovery technique can be useful guidance for COVID-19 drug discovery. Here, we have focused on the structure-activity relationship studies of previous SARS-CoV protease inhibitors and discussed about crucial fragments generated from previous SARS-CoV protease inhibitors important for the lead optimization of SARS-CoV-2 protease inhibitors. This study surely offers different strategic options of lead optimization to the medicinal chemists to discover effective anti-viral agent against the devastating disease, COVID-19.
format Online
Article
Text
id pubmed-7880840
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-78808402021-02-16 Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors? Amin, Sk Abdul Banerjee, Suvankar Gayen, Shovanlal Jha, Tarun Eur J Med Chem Review Article The fascinating similarity between the SARS-CoV and SARS-CoV-2, inspires scientific community to investigate deeper into the SARS-CoV proteases such as main protease (Mpro) and papain-like protease (PLpro) and their inhibitors for the discovery of SARS-CoV-2 protease inhibitors. Because of the similarity in the proteases of these two corona viruses, there is a greater chance for the previous SARS-CoV Mpro and PLpro inhibitors to provide effective results against SARS-CoV-2. In this context, the molecular fragments from the SARS-CoV protease inhibitors through the fragment-based drug design and discovery technique can be useful guidance for COVID-19 drug discovery. Here, we have focused on the structure-activity relationship studies of previous SARS-CoV protease inhibitors and discussed about crucial fragments generated from previous SARS-CoV protease inhibitors important for the lead optimization of SARS-CoV-2 protease inhibitors. This study surely offers different strategic options of lead optimization to the medicinal chemists to discover effective anti-viral agent against the devastating disease, COVID-19. Elsevier Masson SAS. 2021-04-05 2021-02-13 /pmc/articles/PMC7880840/ /pubmed/33618158 http://dx.doi.org/10.1016/j.ejmech.2021.113294 Text en © 2021 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Amin, Sk Abdul
Banerjee, Suvankar
Gayen, Shovanlal
Jha, Tarun
Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
title Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
title_full Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
title_fullStr Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
title_full_unstemmed Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
title_short Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
title_sort protease targeted covid-19 drug discovery: what we have learned from the past sars-cov inhibitors?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880840/
https://www.ncbi.nlm.nih.gov/pubmed/33618158
http://dx.doi.org/10.1016/j.ejmech.2021.113294
work_keys_str_mv AT aminskabdul proteasetargetedcovid19drugdiscoverywhatwehavelearnedfromthepastsarscovinhibitors
AT banerjeesuvankar proteasetargetedcovid19drugdiscoverywhatwehavelearnedfromthepastsarscovinhibitors
AT gayenshovanlal proteasetargetedcovid19drugdiscoverywhatwehavelearnedfromthepastsarscovinhibitors
AT jhatarun proteasetargetedcovid19drugdiscoverywhatwehavelearnedfromthepastsarscovinhibitors